EY US unveils Dr. Barry Patel and Dr. Wade Smith of Galt Companies as an Entrepreneur Of The Year® 2025 Southeast Award finalist.
Galt Pharmaceuticals proudly announces the introduction of Tolectin DS® (Tolmetin Sodium 400mg Capsules), to its growing non-opioid pain product portfolio.
Galt's decision was based on lessons offered by the pandemic, along with research showing an increase in productivity and creativity brought about by the 4-day workweek model.
Galt Pharmaceuticals announced the acquisition of Oravig®, the first and only orally-dissolving buccal tablet for oral thrush, from Fortovia Therapeutics.
Galt Pharmaceuticals announced FDA approval of Orphengesic Forte, a non-opioid, non-controlled, non-addictive alternative for healthcare providers to manage patients suffering from pain.